目的通过生物信息学分析探究m6A甲基化调节因子在肺腺癌中的表达及预后。方法通过TCGA数据库下载516例肺腺癌患者的转录组数据及其临床数据,使用R软件分析比较肺腺癌组织和癌旁组织中20个m6A甲基化调节因子的表达差异,并通过单变量Cox...目的通过生物信息学分析探究m6A甲基化调节因子在肺腺癌中的表达及预后。方法通过TCGA数据库下载516例肺腺癌患者的转录组数据及其临床数据,使用R软件分析比较肺腺癌组织和癌旁组织中20个m6A甲基化调节因子的表达差异,并通过单变量Cox回归分析进行生存分析。通过Consensus Cluster Plus R非监督类的方法进行m6A聚类生存分析。结果16个m6A甲基化调节因子在肺腺癌中差异表达,其中有5个m6A甲基化调节因子(IGF2BP1、IGF2BP3、HNRNPC、RBMX、YTHDC2)与肿瘤分期、7个m6A甲基化调节因子(IGF2BP1、IGF2BP3、HNRNPC、RBMX、METTL3、YTHDF2、METTL14)与T期和2个m6A甲基化调节因子(IGF2BP3、YTHDC2)与N期显著相关。Cox回归分析结果表明6个m6A甲基化调节因子(IGF2BP1、IGF2BP2、IGF2BP3、HNRNPA2B1、HNRNPC、RBM15)是影响肺腺癌患者预后的独立危险因素。结论m6A甲基化调节因子与肺腺癌进展有关,6个m6A甲基化调节因子可以作为预测肺腺癌患者预后的潜在生物标志物。展开更多
目的探究m6A甲基化甲基转移酶RNA结合蛋白15(RNA-binding Motif Protein 15,RBM15)与宫颈癌的相关性及临床意义。方法选取2011年1月1日至2018年1月1日期间于皖南医学院第一附属医院进行诊治的宫颈癌病例132例,另选20例正常宫颈组织病例...目的探究m6A甲基化甲基转移酶RNA结合蛋白15(RNA-binding Motif Protein 15,RBM15)与宫颈癌的相关性及临床意义。方法选取2011年1月1日至2018年1月1日期间于皖南医学院第一附属医院进行诊治的宫颈癌病例132例,另选20例正常宫颈组织病例作为对照,共152例,通过免疫组化法检测RBM15在宫颈癌中和正常宫颈中的表达水平,分析其相关性,并研究其表达量与临床分期及临床病理特征之间的关系。结果RBM15在宫颈癌中的阳性表达率56%显著高于正常宫颈0%(P=0.001),且宫颈癌的期别越高,RBM15表达越强(P=0.002)。复发宫颈癌中RBM15的表达也呈现为随期别逐渐上升的趋势(P=0.156)。RBM15的阳性表达与宫颈癌的肿瘤最大径、淋巴结转移、神经侵犯、脉管癌栓有关(P<0.05),而与肿瘤分级、病理类型、发病年龄、鳞状上皮细胞癌抗原(Squamous cell carcinoma antigen,SCCA)无关(P>0.05)。结论RBM15在宫颈癌中呈高表达,且与宫颈癌分期及临床病理特征具有一定的相关性,RBM15表达升高也会造成宫颈癌患者预后不良,这一发现日后有望成为宫颈癌诊治的新靶点。展开更多
In eukaryotic organisms,the most common internal modification of messenger RNA(m RNA)is N6-methyladenosine(m6A).This modification can be dynamically and reversibly controlled by specific enzymes known as m6A writers a...In eukaryotic organisms,the most common internal modification of messenger RNA(m RNA)is N6-methyladenosine(m6A).This modification can be dynamically and reversibly controlled by specific enzymes known as m6A writers and erasers.The fat-mass and obesity-associated protein(FTO)catalyzes RNA demethylation and plays a critical role in various physiological and pathological processes.Our research identified dynamic alterations in both m6A and FTO during the assembly of primordial follicles,with an inverse relationship observed for m6A levels and nuclear-localized FTO expression.Application of Fto small interfering RNA(si RNA)altered the expression of genes related to cell proliferation,hormone regulation,and cell chemotaxis,and affected RNA alternative splicing.Overexpression of the full-length Fto gene led to changes in m6A levels,alternative splicing of Cdk5,cell proliferation,cell cycle progression,and proportion of primordial follicles.Conversely,overexpression of Fto lacking a nuclear localization signal(NLS)did not significantly alter m6A levels or primordial follicle assembly.These findings suggest that FTO,localized in the nucleus but not in the cytoplasm,regulates RNA m6A demethylation and plays a role in cell proliferation,cell cycle progression,and primordial follicle assembly.These results highlight the potential of m6A and its eraser FTO as possible biomarkers and therapeutic targets.展开更多
目的分析m6A调节因子对膀胱癌(bladder cancer,BC)预后的影响,建立预后预测模型。方法从癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库获取397例BC组织的高通量测序数据和对应的临床病理特征数据。在26个m6A调节因子中,采用单因...目的分析m6A调节因子对膀胱癌(bladder cancer,BC)预后的影响,建立预后预测模型。方法从癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库获取397例BC组织的高通量测序数据和对应的临床病理特征数据。在26个m6A调节因子中,采用单因素Cox回归筛选预后相关的m6A调节因子,利用最小绝对值收敛和选择算子(least absolute shrinkage and selection operator,LASSO)Cox回归分析方法构建BC预后预测模型,比较高低风险组总生存期(overall survival,OS)、免疫检查点相关基因和靶向治疗相关基因表达的差异。通过基因集富集分析比较高低风险组中信号通路的富集情况,采用单样本基因富集分析(single sample gene set enrichment analysis,ssGSEA)和估计恶性肿瘤组织中基质和免疫细胞(estimation of stromal and immune cells in malignant tumors using expression data,ESTIMATE)法评估高低风险组免疫细胞浸润水平的差异。结果YTHDC1、IGF2BP3、LRPPRC、FTO和ALKBH3是BC独立的预后因素。利用LASSO Cox回归方法基于5个m6A调节因子建立BC预后预测风险模型,Kaplan-Meier分析结果提示高低风险组间OS存在显著差异(P<0.001),受试者工作特征(receiver operating characteristic,ROC)曲线下面积为0.665。高风险组在趋化因子、NOD样受体、嘌呤代谢、丙酮酸代谢等信号通路富集,具有丰富的免疫细胞浸润特征,PD-L1、CTLA-4、EGFR和KRAS基因表达更高。结论本研究基于m6A调节因子构建的BC预后预测模型准确性较好,有助于临床上预后判断和分层个体化治疗。展开更多
文摘目的通过生物信息学分析探究m6A甲基化调节因子在肺腺癌中的表达及预后。方法通过TCGA数据库下载516例肺腺癌患者的转录组数据及其临床数据,使用R软件分析比较肺腺癌组织和癌旁组织中20个m6A甲基化调节因子的表达差异,并通过单变量Cox回归分析进行生存分析。通过Consensus Cluster Plus R非监督类的方法进行m6A聚类生存分析。结果16个m6A甲基化调节因子在肺腺癌中差异表达,其中有5个m6A甲基化调节因子(IGF2BP1、IGF2BP3、HNRNPC、RBMX、YTHDC2)与肿瘤分期、7个m6A甲基化调节因子(IGF2BP1、IGF2BP3、HNRNPC、RBMX、METTL3、YTHDF2、METTL14)与T期和2个m6A甲基化调节因子(IGF2BP3、YTHDC2)与N期显著相关。Cox回归分析结果表明6个m6A甲基化调节因子(IGF2BP1、IGF2BP2、IGF2BP3、HNRNPA2B1、HNRNPC、RBM15)是影响肺腺癌患者预后的独立危险因素。结论m6A甲基化调节因子与肺腺癌进展有关,6个m6A甲基化调节因子可以作为预测肺腺癌患者预后的潜在生物标志物。
基金supported by the Natural Science Foundation of Shandong Province,China (ZR2017MC033)National Key Research and Development Program of China (2023YFD1300504)Taishan Scholar Construction Foundation of Shandong Province,China (ts20190946)。
文摘In eukaryotic organisms,the most common internal modification of messenger RNA(m RNA)is N6-methyladenosine(m6A).This modification can be dynamically and reversibly controlled by specific enzymes known as m6A writers and erasers.The fat-mass and obesity-associated protein(FTO)catalyzes RNA demethylation and plays a critical role in various physiological and pathological processes.Our research identified dynamic alterations in both m6A and FTO during the assembly of primordial follicles,with an inverse relationship observed for m6A levels and nuclear-localized FTO expression.Application of Fto small interfering RNA(si RNA)altered the expression of genes related to cell proliferation,hormone regulation,and cell chemotaxis,and affected RNA alternative splicing.Overexpression of the full-length Fto gene led to changes in m6A levels,alternative splicing of Cdk5,cell proliferation,cell cycle progression,and proportion of primordial follicles.Conversely,overexpression of Fto lacking a nuclear localization signal(NLS)did not significantly alter m6A levels or primordial follicle assembly.These findings suggest that FTO,localized in the nucleus but not in the cytoplasm,regulates RNA m6A demethylation and plays a role in cell proliferation,cell cycle progression,and primordial follicle assembly.These results highlight the potential of m6A and its eraser FTO as possible biomarkers and therapeutic targets.
文摘目的分析m6A调节因子对膀胱癌(bladder cancer,BC)预后的影响,建立预后预测模型。方法从癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库获取397例BC组织的高通量测序数据和对应的临床病理特征数据。在26个m6A调节因子中,采用单因素Cox回归筛选预后相关的m6A调节因子,利用最小绝对值收敛和选择算子(least absolute shrinkage and selection operator,LASSO)Cox回归分析方法构建BC预后预测模型,比较高低风险组总生存期(overall survival,OS)、免疫检查点相关基因和靶向治疗相关基因表达的差异。通过基因集富集分析比较高低风险组中信号通路的富集情况,采用单样本基因富集分析(single sample gene set enrichment analysis,ssGSEA)和估计恶性肿瘤组织中基质和免疫细胞(estimation of stromal and immune cells in malignant tumors using expression data,ESTIMATE)法评估高低风险组免疫细胞浸润水平的差异。结果YTHDC1、IGF2BP3、LRPPRC、FTO和ALKBH3是BC独立的预后因素。利用LASSO Cox回归方法基于5个m6A调节因子建立BC预后预测风险模型,Kaplan-Meier分析结果提示高低风险组间OS存在显著差异(P<0.001),受试者工作特征(receiver operating characteristic,ROC)曲线下面积为0.665。高风险组在趋化因子、NOD样受体、嘌呤代谢、丙酮酸代谢等信号通路富集,具有丰富的免疫细胞浸润特征,PD-L1、CTLA-4、EGFR和KRAS基因表达更高。结论本研究基于m6A调节因子构建的BC预后预测模型准确性较好,有助于临床上预后判断和分层个体化治疗。
